Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 3
1979 15
1980 10
1981 6
1982 11
1983 2
1984 4
1985 19
1986 7
1987 19
1988 8
1989 15
1990 16
1991 14
1992 8
1993 12
1994 9
1995 8
1996 14
1997 4
1998 5
1999 2
2000 7
2001 4
2002 6
2003 5
2004 3
2005 2
2006 8
2007 5
2008 1
2009 3
2012 2
2013 3
2014 3
2016 1
2017 4
2019 1
2020 1
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

PubMed (MeSH Keyword) for id: 25774

268 results

Results by year

Filters applied: . Clear all
Page 1
Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT-AML trial.
Jädersten M, Lilienthal I, Tsesmetzis N, Lourda M, Bengtzén S, Bohlin A, Arnroth C, Erkers T, Seashore-Ludlow B, Giraud G, Barkhordar GS, Tao S, Fogelstrand L, Saft L, Östling P, Schinazi RF, Kim B, Schaller T, Juliusson G, Deneberg S, Lehmann S, Rassidakis GZ, Höglund M, Henter JI, Herold N. Jädersten M, et al. J Intern Med. 2022 Dec;292(6):925-940. doi: 10.1111/joim.13553. Epub 2022 Aug 18. J Intern Med. 2022. PMID: 35934913 Free PMC article. Clinical Trial.
Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy.
Rudd SG, Tsesmetzis N, Sanjiv K, Paulin CB, Sandhow L, Kutzner J, Hed Myrberg I, Bunten SS, Axelsson H, Zhang SM, Rasti A, Mäkelä P, Coggins SA, Tao S, Suman S, Branca RM, Mermelekas G, Wiita E, Lee S, Walfridsson J, Schinazi RF, Kim B, Lehtiö J, Rassidakis GZ, Pokrovskaja Tamm K, Warpman-Berglund U, Heyman M, Grandér D, Lehmann S, Lundbäck T, Qian H, Henter JI, Schaller T, Helleday T, Herold N. Rudd SG, et al. EMBO Mol Med. 2020 Mar 6;12(3):e10419. doi: 10.15252/emmm.201910419. Epub 2020 Jan 17. EMBO Mol Med. 2020. PMID: 31950591 Free PMC article.
Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.
Herold N, Rudd SG, Ljungblad L, Sanjiv K, Myrberg IH, Paulin CB, Heshmati Y, Hagenkort A, Kutzner J, Page BD, Calderón-Montaño JM, Loseva O, Jemth AS, Bulli L, Axelsson H, Tesi B, Valerie NC, Höglund A, Bladh J, Wiita E, Sundin M, Uhlin M, Rassidakis G, Heyman M, Tamm KP, Warpman-Berglund U, Walfridsson J, Lehmann S, Grandér D, Lundbäck T, Kogner P, Henter JI, Helleday T, Schaller T. Herold N, et al. Nat Med. 2017 Feb;23(2):256-263. doi: 10.1038/nm.4265. Epub 2017 Jan 9. Nat Med. 2017. PMID: 28067901
Substrates and Inhibitors of SAMHD1.
Hollenbaugh JA, Shelton J, Tao S, Amiralaei S, Liu P, Lu X, Goetze RW, Zhou L, Nettles JH, Schinazi RF, Kim B. Hollenbaugh JA, et al. PLoS One. 2017 Jan 3;12(1):e0169052. doi: 10.1371/journal.pone.0169052. eCollection 2017. PLoS One. 2017. PMID: 28046007 Free PMC article.
268 results